Related Experiment Videos

Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial

R Michael Kirchner1, J Dawn Abbott

  • 1Department of Cardiology, Rhode Island Hospital, Brown Medical School, Providence, RI 02903, USA.

Vascular Health and Risk Management
|January 9, 2010
PubMed

Insights

Drug-eluting stents (DES) significantly reduce restenosis compared to bare metal stents. The Xience V stent demonstrated efficacy and safety in the SPIRIT trial program, offering improved outcomes in interventional cardiology.

Area of Science:

  • Interventional Cardiology
  • Biomedical Engineering
  • Clinical Trials

Background:

  • Drug-eluting stents (DES) have revolutionized interventional cardiology by reducing restenosis and target vessel revascularization compared to bare metal stents.
  • Several DES are available, including first-generation sirolimus-eluting and paclitaxel-eluting stents, and second-generation everolimus-eluting and zotarolimus-eluting stents.

Purpose of the Study:

  • To provide a comprehensive assessment of the Xience V everolimus-eluting stent.
  • To review data from pre- and post-approval randomized controlled trials and registry studies within the SPIRIT clinical trial program.
  • To discuss the implications of mid-term outcomes for interventional practice.

Main Methods:

  • Analysis of data from the SPIRIT clinical trial program, including randomized controlled trials and registry studies.
  • Assessment of pre- and post-approval data for the Xience V stent.
  • Review of recently published mid-term outcomes.

Main Results:

  • The Xience V stent was approved based on clinical efficacy and safety data from the SPIRIT trials.
  • In the SPIRIT trials, Xience V was superior to the Vision bare metal stent for target vessel failure at 9 months.
  • Xience V was noninferior to the paclitaxel-eluting stent for target vessel failure at 9 months.

Conclusions:

  • The Xience V stent has demonstrated significant clinical efficacy and safety.
  • Data from the SPIRIT clinical trial program support the use of Xience V in interventional cardiology.
  • Mid-term outcomes continue to support the role of Xience V in improving patient care.

Keywords:
Xience Vcobalt-chromiumdrug-eluting stenteverolimuspercutaneous coronary intervention

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...